Loading news...
The average of price targets set by Wall Street analysts indicates a potential upside of 55% in Immunovant (IMVT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
DURHAM, N.C. and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the third quarter ended December 31, 2025, and provide a business update at 8:00 a.m. ET on Friday, February 6, 2026.
SG Americas Securities LLC raised its stake in Immunovant, Inc. (NASDAQ: IMVT) by 679.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 62,598 shares of the company's stock after purchasing an additional 54,570 shares during the quarter. SG
Northwest Biotherapeutics (OTCMKTS:NWBO - Get Free Report) and Immunovant (NASDAQ: IMVT - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, dividends, risk and analyst recommendations. Valuation and Earnings This table compares Northwest Biotherapeutics and
The mean of analysts' price targets for Immunovant (IMVT) points to a 47.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
NEW YORK, Jan. 5, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Immunovant, Inc. (NASDAQ: IMVT) on behalf of the company's shareholders. The investigation seeks to determine whether Immunovant, Inc.'s directors breached their fiduciary duties in connection with recent corporate actions.
Roivant Sciences Ltd. acquired 16,666,666 shares in a single open-market purchase on Dec. 12, 2025, for a transaction value of ~$350.0 million at $21.00 per share.
In the past week or so, secondary offerings from biotechs Immunovant Inc. (NASDAQ: IMVT), Kymera Therapeutics Inc.
Stock News Ford pivots from full EV to hybrids and storage: Ford Motor (F) will discontinue the allâelectric Fâ150 Lightning and replace it with a plugâin
Stock News iRobot enters Chapter 11: iRobot (IRBT) filed for Chapter 11 and agreed to be acquired by contract manufacturer Picea Robotics, saying operations and
Immunovant (IMVT) shifts primary focus to IMVT-1402, a next-generation anti-FcRn, targeting Graves' Disease with potential best-in-class IgG reductions. I downgrade IMVT from "Strong Buy" to "Buy" due to competitive TED landscape and de-emphasis on batoclimab, despite robust upcoming catalysts. IMVT-1402 aims to address unmet needs in relapsed or uncontrolled GD patients, with pivotal data readouts expected in 2027 for additional indications like Myasthenia Gravis and difficult-to-treat rheumatoid arthritis.
Roivant (NASDAQ: ROIV) outlined accelerated timelines and expanded commercial ambitions for several late-stage programs.
NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced the pricing of an underwritten offering of its common stock, with anticipated gross proceeds to Immunovant of approximately $550 million, before deducting underwriting discounts and commissions and other expenses payable by Immunovant in connection with the transaction. Roivant Sciences Ltd., the Company's controlling stockholder, has agreed to purchase shares in the offering. All of the shares are to be sold by Immunovant.
Capital Fund Management S.A. acquired a new position in shares of Immunovant, Inc. (NASDAQ: IMVT) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 55,524 shares of the company's stock, valued at approximately $888,000. A number of other hedge funds and
Immunovant posts a wider Q2 loss as R&D spending rises, but progress on IMVT-1402 and batoclimab fuels its pipeline momentum.
Immunovant, Inc. ( IMVT ) Q2 2026 Earnings Call November 10, 2025 8:00 AM EST Company Participants Conference Call Participants Stephanie Lee Griffin - Roivant Sciences Ltd. Matthew Gline - Roivant Sciences Ltd.
Study in uncontrolled Graves' disease (GD) patients treated for 24 weeks showed first-ever potentially disease-modifying outcome with six-month off-treatment data IMVT-1402 development is progressing with potentially registrational studies in GD, myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), difficult-to-treat rheumatoid arthritis (D2T RA) and Sjögren's disease (SjD) remains on track Immunovant remains on track for the first of the two batoclimab Phase 3 thyroid eye disease (TED) studies to read out before the end of calendar year 2025. However, due to evolving competitive dynamics, the Company anticipates sharing topline results from both TED studies concurrently in the first half of calendar year 2026 Current cash balance provides runway for announced indications through GD readout expected in 2027 NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported its financial results for the second quarter ended September 30, 2025.
NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the second quarter ended September 30, 2025, and provide a business update at 8:00 a.m. ET on Monday, November 10, 2025.
Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock?
Immunovant stock jumps 11% after new batoclimab study results showed durable thyroid hormone control in Graves' disease patients.